Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

+420 224 910 672

(from 09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

+420 224 910 672

(09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

BREXIT – What to Expect from the Regulatory and Pharmacovigilance Perspectives

Date: 12.11.2020

Time: 11:00 CET

Price: Free of Charge

On Thursday 12th November 2020, at 11:00 CET (Central European Time, GMT+2), ELC will be hosting a webinar providing an overview on BREXIT – What to Expect from the Regulatory and Pharmacovigilance Perspectives

The presenters will be Marco Rubinstein, CEO of ELC Group, Dr. Prashanth BSB, Medical Writing and EUQPPV in ELC Group and Vikash Patel, Senior Regulatory Consultant.

We are going to take you through the following topics:

  1. Licensing Routes & Supply Chain Complexity
  2. Life Cycle Management
  3. Northern Ireland Conundrum
  4. Pharmacovigilance (QPPV and National Contact Person)
  5. Pharmacovigilance System Master File & Submission

Please note that the number of participants is limited.

To register, click here